Basic Metabolic Panel without Calcium
The Basic Metabolic Panel without Calcium measures six core analytes—sodium, potassium, chloride, bicarbonate, BUN, creatinine, and glucose—providing a rapid assessment of fluid and electrolyte balance, renal function, and glycaemic control.
8
Biomarkers
Blood (serum)
Sample
1 business day
Turnaround
Preferred (8–12 hours) for glucose; not required for other analytes
Fasting
What is the BMP-6 test?
The Basic Metabolic Panel without Calcium is a six-analyte chemistry profile measuring the core electrolytes (sodium, potassium, chloride, bicarbonate), kidney function markers (BUN, creatinine), and glucose. It provides a rapid snapshot of fluid and electrolyte balance, renal function, and glycaemic control, making it one of the most frequently ordered laboratory panels in both acute and ambulatory settings. Practitioners order it to screen for metabolic derangements, to evaluate acute illness, and to monitor chronic conditions and the metabolic effects of medications. In clinical decision-making the panel is interpreted as a constellation: the electrolytes reveal volume status and acid-base disturbances; BUN and creatinine together assess kidney function and distinguish pre-renal from intrinsic azotaemia via the BUN:creatinine ratio; glucose screens for dysglycaemia. The anion gap—calculated from sodium, chloride, and bicarbonate—further classifies metabolic acidosis. Because it omits calcium, this variant is slightly more economical than the traditional eight-analyte basic metabolic panel and is ordered when calcium status is not a concern or has been measured separately.
What does the BMP-6 test measure?
Sodium is the principal extracellular cation, accounting for most of plasma osmolality and determining extracellular fluid volume. Its concentration is tightly regulated by thirst, antidiuretic hormone, and renal sodium handling. Because water balance profoundly affects measured sodium concentration, dysnatraemia typically reflects disturbances in water homeostasis rather than total body sodium per se.
Hyponatraemia is the most common electrolyte disorder in hospital and ambulatory practice, prompting evaluation of volume status, hormone excess (SIADH, adrenal insufficiency, hypothyroidism), and medication effects. Hypernatraemia signals free water deficit or, less commonly, salt overload. Both extremes carry neurological risk when severe or rapid.
Potassium is the major intracellular cation; only a small fraction resides in extracellular fluid, yet that fraction determines membrane potential in cardiac and skeletal muscle. Renal excretion is tightly regulated by aldosterone, distal sodium delivery, and acid-base status, and transcellular shifts (driven by insulin, pH, and adrenergic tone) can change serum potassium rapidly.
Hypokalaemia predisposes to arrhythmia, muscle weakness, and metabolic alkalosis; common causes include diuretics, gastrointestinal losses, and hyperaldosteronism. Hyperkalaemia is a medical emergency when severe, often driven by renal impairment, potassium-sparing diuretics, ACE inhibitors, or transcellular shifts in acidosis or tissue injury. Pre-analytical pseudohyperkalaemia from haemolysis or delayed separation is a frequent false alarm.
Chloride is the predominant extracellular anion, accompanying sodium in maintaining electroneutrality and osmotic balance. Renal chloride reabsorption parallels sodium to a large degree, though the two can dissociate in metabolic acid-base disorders. Gastric secretion is rich in chloride, so vomiting causes hypochloraemic alkalosis.
Chloride is essential to calculating the anion gap, which helps classify metabolic acidosis. Hypochloraemia accompanies many causes of metabolic alkalosis (vomiting, loop diuretics), while hyperchloraemia can result from normal-anion-gap acidosis (renal tubular acidosis, diarrhoea) or from high chloride intake and fluids.
Total CO₂ represents serum bicarbonate plus dissolved carbon dioxide, with bicarbonate comprising more than 95 per cent in venous samples at physiological pH. Bicarbonate is the principal extracellular buffer, regulated by renal retention and excretion in response to metabolic and respiratory acid-base disturbances.
Low bicarbonate signals metabolic acidosis (renal failure, ketoacidosis, lactic acidosis, renal tubular acidosis) or respiratory alkalosis with renal compensation. High bicarbonate suggests metabolic alkalosis (vomiting, diuretic use, volume contraction) or compensated respiratory acidosis. The anion gap and clinical context are essential to distinguish causes.
Urea is synthesised in the liver from ammonia generated during amino-acid catabolism and is excreted by the kidneys. Its plasma concentration reflects the balance between protein intake, hepatic urea synthesis, and renal clearance. Because urea is freely filtered and variably reabsorbed along the nephron—especially when urine flow is low—BUN is influenced by both GFR and volume status.
Elevated BUN can signal reduced GFR (acute or chronic kidney disease), volume depletion (pre-renal azotaemia), high protein intake, gastrointestinal bleeding, or catabolic states. A disproportionately high BUN relative to creatinine (BUN:creatinine ratio above 20:1) suggests pre-renal azotaemia or gastrointestinal bleeding. Low BUN is less clinically significant but may accompany liver disease, overhydration, or very low protein intake.
Creatinine is a breakdown product of muscle creatine phosphate, released into the circulation at a relatively constant rate proportional to muscle mass and filtered freely at the glomerulus with minimal tubular reabsorption. Its plasma concentration inversely reflects glomerular filtration rate, making it the most widely used endogenous marker of kidney function, though it is insensitive to early GFR decline.
Creatinine is the cornerstone of estimated GFR equations (CKD-EPI, MDRD) used to stage chronic kidney disease and to dose renally cleared drugs. Acute rises signal acute kidney injury; chronic elevation reflects chronic kidney disease. Creatinine is influenced by muscle mass, so lower values are normal in older adults, women, and those with low muscle mass, while bodybuilders and high-meat consumers may have values at the upper reference limit without renal impairment.
Glucose is the primary circulating fuel for most tissues and the sole obligate substrate for the brain under normal conditions. Its concentration is tightly regulated by insulin, glucagon, and counter-regulatory hormones, with the liver and kidney modulating production and uptake. Fasting glucose reflects hepatic glucose output balanced against basal insulin secretion and peripheral glucose disposal.
Fasting glucose is the first-line screening test for diabetes (≥126 mg/dL on two occasions) and pre-diabetes (100–125 mg/dL). Random or non-fasting glucose is less specific but values ≥200 mg/dL with symptoms are diagnostic. Hypoglycaemia (below 70 mg/dL) prompts evaluation for excess insulin, adrenal insufficiency, or glycogen-storage disorders. Glucose is time-sensitive and requires prompt separation to avoid ex vivo glycolysis by blood cells.
The BUN:creatinine ratio is a derived marker that compares two filtration products with differing tubular handling. Because urea reabsorption increases when tubular flow slows (as in volume depletion), while creatinine remains relatively constant, the ratio rises in pre-renal states and falls when urea production is low or tubular flow is high.
A ratio above 20:1 suggests pre-renal azotaemia (volume depletion, heart failure, renal artery stenosis) or increased urea production (gastrointestinal bleeding, high protein intake, catabolic illness). A ratio below 10:1 can be seen with overhydration, liver disease (reduced urea synthesis), or a low-protein diet. Intrinsic renal disease typically preserves the ratio near the reference range, so the ratio helps distinguish pre-renal from intrinsic acute kidney injury.
Why is the BMP-6 test ordered?
- Evaluation of acute illness, dehydration, or suspected electrolyte disturbance (vomiting, diarrhoea, altered mental state, syncope)
- Screening and monitoring of chronic kidney disease, with creatinine used to calculate estimated GFR and stage disease
- Baseline and serial monitoring of patients on diuretics, ACE inhibitors, ARBs, or other medications affecting electrolytes and renal function
- Assessment of acid-base status in suspected metabolic acidosis or alkalosis, using bicarbonate and the calculated anion gap
- Screening for diabetes and pre-diabetes via fasting glucose, or monitoring glycaemic control in known diabetes
- Pre-operative or hospital admission metabolic screening to identify unrecognised electrolyte, renal, or glycaemic abnormalities
- Evaluation of hypertension, particularly when secondary causes (renal disease, hyperaldosteronism) are considered
- Monitoring of parenteral nutrition, intravenous fluid therapy, or any intervention that may alter fluid and electrolyte balance
Sample collection and turnaround
Sample type
Blood (serum)
Fasting required
Preferred (8–12 hours) for glucose; not required for other analytes
Collection method
Venipuncture at patient service centre
Turnaround
1 business day
Collection notes
Phlebotomy at a Quest patient service centre. Fasting is preferred for accurate glucose measurement but not mandatory for electrolytes, BUN, or creatinine. Avoid vigorous fist clenching or prolonged tourniquet application, which can spuriously raise potassium. Separate serum from cells promptly (ideally within 30 minutes) to prevent ex vivo glycolysis lowering glucose and haemolysis raising potassium.
Specimen requirements
Minimum 1.0 mL serum in a gel separator tube (SST). Reject grossly haemolysed specimens for potassium. Glucose is stable refrigerated for up to 24 hours after separation; electrolytes and renal markers are stable for several days.
What can affect BMP-6 results?
Red cells are rich in potassium; haemolysis releases intracellular potassium into serum, causing pseudohyperkalaemia. Glucose may also be spuriously lowered by ex vivo glycolysis. Grossly haemolysed specimens should be rejected.
Blood cells continue to metabolise glucose after collection, lowering measured glucose by up to 10 mg/dL per hour at room temperature. Prompt separation or the use of a glycolysis inhibitor tube is essential for accurate glucose.
Vigorous fist pumping or a prolonged tourniquet can cause localised acidosis and potassium efflux from muscle, spuriously raising serum potassium by 0.5–1.0 mmol/L.
Diuretics alter sodium, potassium, chloride, and bicarbonate; ACE inhibitors and ARBs raise potassium and can worsen renal function; NSAIDs reduce GFR; corticosteroids can raise glucose and cause hypokalaemic alkalosis. A complete medication history is essential to interpretation.
High protein intake and dehydration raise BUN disproportionately to creatinine, elevating the BUN:creatinine ratio. Overhydration dilutes all analytes, particularly BUN and sodium.
Creatinine production is proportional to muscle mass, so bodybuilders and those with high muscle mass have higher baseline creatinine without renal impairment. A recent high-protein or high-meat meal transiently raises both BUN and creatinine.
What do BMP-6 results mean?
Elevated
Sodium: hypernatraemia from free water deficit (diabetes insipidus, hypodipsia, insensible losses) or rarely salt excess. Potassium: hyperkalaemia from renal impairment, potassium-sparing diuretics, ACE inhibitors/ARBs, acidosis, haemolysis (pseudohyperkalaemia), or tissue breakdown. Chloride: hyperchloraemia in normal-anion-gap acidosis (RTA, diarrhoea) or excessive saline. Bicarbonate: metabolic alkalosis (vomiting, diuretics, volume contraction) or compensated respiratory acidosis. BUN: azotaemia from reduced GFR (pre-renal, intrinsic renal, post-renal), high protein intake, GI bleeding, or catabolism. Creatinine: reduced GFR from acute or chronic kidney disease. Glucose: hyperglycaemia from diabetes, pre-diabetes, stress, or corticosteroids. BUN:Cr ratio >20:1: pre-renal azotaemia or increased urea production.
Normal
A normal panel reassures that electrolyte balance, renal function, and fasting glycaemia are within expected ranges at the time of sampling. It does not exclude early or compensated disease—mild chronic kidney disease may present with creatinine at the upper reference limit but still within the interval, and pre-diabetes may manifest as fasting glucose in the high-normal range (95–99 mg/dL). Serial trends and correlation with estimated GFR are more informative than a single normal result.
Reduced
Sodium: hyponatraemia from SIADH, adrenal insufficiency, hypothyroidism, diuretics, or water overload. Potassium: hypokalaemia from diuretics, GI losses (vomiting, diarrhoea), hyperaldosteronism, or inadequate intake. Chloride: hypochloraemia in metabolic alkalosis (vomiting, diuretics) or SIADH. Bicarbonate: metabolic acidosis (ketoacidosis, lactic acidosis, renal failure, RTA) or compensated respiratory alkalosis. BUN: low protein intake, liver disease, overhydration, or pregnancy. Creatinine: low muscle mass, malnutrition, or, rarely, severe liver disease. Glucose: hypoglycaemia from excess insulin, sulphonylureas, adrenal insufficiency, or glycogen-storage disorders. BUN:Cr ratio <10:1: overhydration, liver disease, or very low protein intake.
Note: Interpret each analyte in the context of the others—the anion gap (sodium minus the sum of chloride and bicarbonate) is essential to classifying metabolic acidosis, and the BUN:creatinine ratio distinguishes pre-renal from intrinsic azotaemia. Pseudohyperkalaemia from haemolysis is common; repeat a haemolysed specimen before treating. Creatinine-based eGFR equations underperform at extremes of muscle mass and in acute kidney injury. Glucose requires fasting for diagnostic accuracy; a non-fasting sample is screening only. Reference limits differ by laboratory and assay, so serial results are best compared within the same performing lab.
Frequently asked questions
The traditional basic metabolic panel includes calcium as an eighth analyte. The without-calcium variant measures only six analytes—sodium, potassium, chloride, bicarbonate, BUN, creatinine, and glucose—and is ordered when calcium status is not a clinical concern or has been measured separately, offering a slightly more economical option.
How to access the BMP-6 test
The BMP-6 reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.
Create Free AccountAbout this page
Published: October 7, 2026
Last reviewed: October 7, 2026
- KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. (2013)
- American Diabetes Association. Standards of Care in Diabetes. (2025)
- Adrogué HJ, Madias NE. Diagnosis and treatment of hyponatremia. Am J Kidney Dis. (2014)
- Palmer BF, Clegg DJ. Electrolyte and acid-base disturbances in patients with diabetes mellitus. N Engl J Med. (2015)
- Inker LA, et al. New creatinine- and cystatin C–based equations to estimate GFR without race. N Engl J Med. (2021)
This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.
Related tests
metabolic diabetes
CMP
The Comprehensive Metabolic Panel is a 14-analyte serum chemistry panel simultaneously evaluating renal function (creatinine, BUN, eGFR), hepatic function (ALT, AST, total bilirubin, albumin, total protein), metabolic status (glucose, calcium), and electrolyte-acid-base homeostasis (sodium, potassium, chloride, bicarbonate) from a single fasting serum specimen.
comprehensive panels
CBC with Differential
The Complete Blood Count with Differential quantifies and characterises white blood cells (with 5-part leucocyte differential), red blood cells (with erythrocyte indices including MCV, MCH, MCHC, and RDW), and platelets (with mean platelet volume) from a single EDTA whole blood specimen.
metabolic diabetes
HbA1c
The haemoglobin A1c (HbA1c) test measures glycated haemoglobin in whole blood, reflecting average blood glucose over the preceding two to three months. It is the standard test for diagnosing type 2 diabetes and prediabetes and for monitoring long-term glycaemic control, and it does not require fasting.